Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of a recombinant trivalent rotavirus subunit vaccine in healthy infants and young children
ChiCTR2100049788Phase 2Not yet recruiting
- Sponsor
- Henan Provincial Center for Disease Control and Prevention
- Start
- Jul 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant trivalent subunit rotavirus vaccine in rotaviral diarrhea (11 arms), sponsored by Henan Provincial Center for Disease Control and Prevention. Primary endpoints: Adverse events, Anti-rotavirus IgG seroresponse and geometric mean titer and 2 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
recombinant trivalent subunit rotavirus vaccine
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on ChiCTR2100049788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049788.